Clinical Trial Update: Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 3]

View source ↗

Summary

Phase 3 trial update for darbepoetin alfa in anemic low or intermediate-1 risk myelodysplastic syndrome patients; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Amgen | Conditions: MDS | Phase 3 | Status: COMPLETED | Results posted: 2016-12-05